Regeneron Reports Second Quarter 2022 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Oppenheimer Positive on Regeneron Pharma (REGN), 'We anticipate material pipeline readouts in 2H22/1H23'
August 4, 2022 10:21 AM EDTOppenheimer analyst Hartaj Singh reiterated an Outperform rating and $775.00 price target on Regeneron Pharma (NASDAQ: REGN).
The analyst comments "Regeneron (REGN) reported 2Q22 sales/earnings on 8/3 and provided a business update. Sales modestly outpaced OPCO expectations while earnings beat our estimates by... More
Regeneron (REGN) Tops Q2 EPS by $1.17
August 3, 2022 6:38 AM EDTRegeneron (NASDAQ: REGN) reported Q2 EPS of $9.77, $1.17 better than the analyst estimate of $8.60. Revenue for the quarter came in at $2.86 billion versus the consensus estimate of $2.79 billion.
For earnings history and earnings-related data on Regeneron (REGN) click here.
... More